Why It Matters

Viatris Inc. is aiming to shape drug policy affecting several high-stakes areas.

Congressional efforts to streamline generic drug approvals through the Increasing Transparency in Generic Drug Applications Act could accelerate Viatris’s market entry timelines. Patent reform legislation like the PREVAIL Act would restrict anticompetitive settlement practices that currently slow generic competition. Supply chain initiatives would create new incentives for domestic manufacturing—directly benefiting Viatris’s production plans.

By the Numbers

Viatris Inc. spent $640,000 on in-house lobbying in Q3 2025 and approximately $17.3 million since 2020.

Viatris maintained its in-house team of five experienced lobbyists while continuing relationships with Holland & Knight LLP, Ferox Strategies LLC, and other retained firms. The in-house team includes former congressional staff: William Michael Dent worked on the Senate HELP Committee, David L. Marin served as Republican Staff Director for the House Oversight Committee, and Anne E. Wilson worked for Rep. Anna Eshoo on the House Energy and Commerce Committee.

The company previously retained external firms including Blue Ridge Law & Policy PC, West Front Strategies LLC, and S-3 Group.

The Agenda

Viatris Inc. lobbied on multiple issues critical to generic and biosimilar manufacturers in Q3 2025:

  • Healthcare policy: Inflation Reduction Act implementation, Medicare Part D formulary design, generic drug tiering, drug shortages, and the Medicaid Generics Penalty
  • Specific legislation: H.R. 1843 / S. 1302 (Increasing Transparency in Generic Drug Applications Act), S. 1553 (PREVAIL Act)
  • Trade and supply chain: Generic medicines supply chain issues and domestic manufacturing
  • Intellectual property: Patent settlements, generic medicine IP issues, and anticompetitive patent practices

Between The Lines

Congress is pursuing bipartisan legislation directly aligned with Viatris’s priorities. The Increasing Transparency in Generic Drug Applications Act aims to streamline FDA approval processes. Patent reform efforts are gaining momentum, with the Senate Judiciary Committee advancing bills to end "pay-for-delay" settlements.

Supply chain resilience has emerged as a national security priority. The PILLS Act proposes tax incentives for domestic generic drug production. Senator Rick Scott led hearings on rebuilding U.S. medicine supplies, signaling GOP interest in onshoring pharmaceutical manufacturing.

Congress also examined the health of the biosimilar market and ways to increase adoption of lower-cost biosimilars.

Competitive Landscape

Viatris faces competition from other pharmaceutical companies lobbying on similar issues. Fresenius Kabi USA LLC also engaged on the Increasing Transparency in Generic Drug Applications Act, Part D formulary design, and PREVAIL Act, indicating coordinated industry-wide efforts on critical policy issues.

The Bottom Line

Viatris’ priorities align with bipartisan congressional efforts to lower drug costs and strengthen domestic pharmaceutical manufacturing, positioning it strategically amid ongoing Inflation Reduction Act implementation and evolving regulatory priorities.

Spot something wrong? Report an issue with this article